Form 4: NewAmsterdam Pharma Director Buys Shares

James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V., purchased 471 ordinary shares indirectly on August 11, 2025.

Summary

• James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V. (NAMS), reported an indirect purchase of ordinary shares.
• The transaction involved the acquisition of 471 ordinary shares at a weighted average price of $23.9787 per share.
• The shares were purchased in multiple transactions with prices ranging from $23.91 to $24.00, inclusive.
• The transaction date was August 11, 2025.
• Following this transaction, the indirect beneficial ownership attributed to Mr. Topper includes 3,026,604 ordinary shares held by Frazier Life Sciences X, L.P. and 3,801,000 ordinary shares held by Frazier Lifesciences Sponsor LLC.
• Mr. Topper disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The purchase of shares by a Director and 10% Owner typically indicates confidence in the company's future, which is a positive signal for investors. The transaction size is small relative to total holdings, but the act of buying is generally favorable.

Positives

• A Director and 10% Owner, James N. Topper, purchased additional shares, which can signal confidence in the company's future prospects.
• The purchase was made at a specific valuation point, with a weighted average price of $23.9787 per share.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider share purchase by a Director and 10% Owner of NewAmsterdam Pharma Co N.V. is a routine disclosure of a change in beneficial ownership. While it signals insider confidence, it does not inherently provide broader insights into industry trends or competitive landscape beyond the specific company's stock activity.

Comparison to Industry Standards

• This filing details an insider share purchase, which is a common occurrence across publicly traded companies.
• The specific transaction size of 471 shares is relatively small compared to the total indirect holdings of over 6.8 million shares, and its significance should be viewed in the context of the insider's overall portfolio and the company's market capitalization.
• There are no specific comparable companies or projects mentioned in this transactional filing to assess against global benchmarks.

Related Party Transactions

• The reported transaction is a purchase of ordinary shares by James N. Topper, a Director and 10% Owner, through entities where he has indirect beneficial ownership (Frazier Life Sciences X, L.P. and Frazier Lifesciences Sponsor LLC). This constitutes a related party transaction as it involves an insider.

Stakeholder Impact

• Shareholders: The purchase by a significant insider may be perceived positively, potentially boosting investor confidence and signaling management's belief in the company's value.
• Employees, Customers, Suppliers, Creditors: This specific transactional filing has no direct or immediate impact on these stakeholders.

Key Dates

Recommendation

The purchase of shares by a Director and 10% Owner, James N. Topper, signals confidence in NewAmsterdam Pharma Co N.V. However, the transaction size of 471 shares is relatively small compared to his total indirect beneficial ownership of over 6.8 million shares. While insider buying is generally a positive indicator, this specific Form 4 filing does not provide sufficient additional financial or strategic details to warrant a 'strong buy' recommendation. It primarily reinforces a 'hold' position for existing investors or suggests further due diligence for potential investors, as it indicates an insider's belief in the current valuation.

Keywords

NewAmsterdam Pharma, NAMS, James N. Topper, Director, 10% Owner, Insider Trading, Share Purchase, SEC Form 4, Beneficial Ownership, Frazier Life Sciences